BACKGROUND: Depression greatly burdens subSaharan Africa, especially populations living with HIV/ AIDS, for whom few validated depression scales exist. Patient Health Questionnaire-9 (PHQ-9), a brief dualpurpose instrument yielding DSM-IV diagnoses and severity, and PHQ-2, an ultra-brief screening tool, offer advantages in resource-constrained settings.
INTRODUCTION
More than 70% of all deaths attributable to HIV/AIDS are in sub-Saharan Africa, with approximately 6.1% of adults living with HIV in Kenya in 2005 1 . The social, economic and health impact of depression in sub-Saharan Africa is also great, where depression is associated with mortality [2] [3] [4] [5] , work disability [4] [5] [6] [7] , lower quality of life 5, [8] [9] [10] [11] [12] , risk of heart disease 13 and high-risk behaviors for contracting HIV infection 14 . With one exception 15 , the sparse literature on depression among individuals living with HIV/AIDS in sub-Saharan Africa has shown elevated rates of depression relative to community samples 3, 8, 10, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] , consistent with western countries [26] [27] [28] [29] . Thus, there is an urgency to incorporating mental health into HIV/ AIDS treatment programs in sub-Saharan Africa, including western Kenya [30] [31] [32] [33] [34] [35] .
Depression in sub-Saharan Africa presents in forms (culturespecific idioms, somatic, based on interpersonal relationships or spiritual in nature) that may obscure detection [36] [37] [38] . However, depression exists at possibly higher prevalence rates than in western countries 37 according to 16 studies 4, 5, 7, [9] [10] [11] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] , and an additional 13 studies cited in 37 , of community and non-HIVspecific clinic populations, with generally higher rates for women than men 37, 43 . Finally, depression is reasonably easy to elicit when sought and present 37 . Few studies have validated depression instruments for subSaharan cultures (MDD), other depressive disorder (ODD) and any depressive disorder (i.e., MDD or ODD).
The PHQ-9 has been validated in western countries regarding construct validity 53, 54, 57, [59] [60] [61] [62] [63] [64] , diagnostic accuracy 53, 57, 58, 62, [64] [65] [66] [67] [68] , sensitivity to change 61, 69, 70 , responsiveness to treatment [71] [72] [73] , internal consistency 56, 57, 63, 65, 74, 75 , test-retest reliability 56, 57, 62, 73 and realistic estimates of population base rates 74 . The PHQ-2 (i.e., the first two items of the PHQ-9) is an ultra-brief and accurate screening tool 58, [76] [77] [78] . The PHQ-9 has been validated in chronically ill populations 58, 62, 63, 79 . However, only one report studied individuals living with HIV (in the US); the PHQ-9 demonstrated better diagnostic accuracy than the provider report 27 . Only three published studies administered the PHQ-9 in sub-Saharan Africa, showing good psychometric properties in urban Kenyan low-literacy cancer patients 11 , Nigerian university students 46 and educated Nigerian army personnel 80 .
The present study addresses two questions in the context of adults living with HIV/AIDS in western Kenya:
1. What is the validity and reliability of the PHQ-9 for assessing DSM-IV depressive disorders and depression severity? 2. What are the operating characteristics of the PHQ-2 as a diagnostic screening tool for determining PHQ-9 DSM-IV diagnoses of MDD and any depressive disorder?
METHODS

Participant Recruitment
The protocol was approved by the Institutional Research and Ethics Committee at Moi University (Kenya) and the Committee on Protection of Human Subjects at Indiana UniversityBloomington (US). Of those attending routine psychosocial support groups during the study week at Moi University Teaching and Referral Hospital in Eldoret, Kenya, 100% agreed to participate when invited by a research assistant 32 . These support groups are a component of a comprehensive HIV prevention and care program known as the Academic Model for the Prevention and Treatment of HIV/AIDS (AMPATH) [81] [82] [83] [84] .
Data Collection
An informed consent statement was read to individuals by research assistants in English (or Swahili if preferred) and signed by a "witness" (research assistant) to protect anonymity. Participants completed a self-administered paperbased baseline questionnaire in English (n=397). Research assistants were available to translate unfamiliar terms using an unpublished Swahili version our team developed through translation and back translation. Every other participant was invited, excluding focus group participants, to complete a retest assessment 1 week later (n =187). Analyses were based on 347 participants who had no missing baseline PHQ-9 items. Test-retest analyses included 145 participants who had no missing baseline or retest PHQ-9 items. Focus groups were conducted during the first week among baseline participants. The most recent CD4 count within the previous 6 months was abstracted from medical charts.
Measures
Depression was assessed with the PHQ-9 (Appendix) 53 . The PHQ-9 scoring algorithm for DSM-IV diagnoses of MDD and ODD is described elsewhere (p. 607) 57 . The PHQ-9 total score ranges from 0 to 27 with five severity categories: minimal (0-4), mild (5-9), moderate (10) (11) (12) (13) (14) , moderately severe (15) (16) (17) (18) (19) and severe (20) (21) (22) (23) (24) (25) (26) (27) . General health perception rating was administered 85 : "In general how would you rate your overall health right now?" Ratings were from excellent (1) to poor (5). Recommended scoring was used: 1=5, 2=4.36, 3=3.43, 4=1.99 and 5=1, rescaled 0-100; a higher score represents better perceived health 85 .
Statistical Analysis
All analyses were performed with SPSS, except weighted kappa was computed with SAS. Significance level was 0.05.
Construct validity. A significant relationship between the PHQ-9 and general health rating 62, 63 or functional impairment scales 53, 54, 57, 60, 64, 76 supports construct validity, because depression is known to negatively impact perceived health 60 . Analysis of covariance (ANCOVA) was used to compare PHQ-9 diagnostic and severity categories (independent variable) on general health rating (dependent variable), while adjusting, consistent with previous studies 53, 54, 60 , for gender, age and education (≥ Form 1-2 vs ≤ Standard 4-8). The false discovery rate method controlled the proportion (0.05) of falsely rejected null hypotheses for multiple post-hoc pair-wise comparisons of depression categories 86, 87 . Results were descriptively compared to two large, demographically diverse, US validation samples 53, 54 .
Construct validity. Factor analysis was performed using principal component extraction, initial communalities of 1.0 and Varimax rotation. Number of factors was determined with the scree plot 88 . Item discrimination was assessed with corrected item-total correlations 89 .
Content validity. Narrative data were collected from four singlegender 90 focus groups using cognitive interviewing 91 . Sample sizes were four and seven for female groups, and five and eight for male groups. There were two facilitators in each group (one American, one Kenyan). Participants could answer in Swahili when unsure of English terminology. Discussions examined meaning, comprehension and interpretation of PHQ-9, and lasted an average of 1.5 h.
Reliability. Internal consistency was assessed with coefficient alpha. Test-retest reliability was assessed for (1) PHQ-9 total score with an intraclass correlation coefficient (ICC) using agreement and consistency indices with occasions as random 92 , (2) PHQ-9 DSM-IV diagnoses with a kappa coefficient of chance-corrected agreement 93 and (3) PHQ-9 severity categories with weighted kappa 94 using Fleiss-Cohen quadratic weights 95 .
Operating characteristics of the PHQ-2. The PHQ-2 operating characteristics were calculated for PHQ-9 MDD and separately for any PHQ-9 depressive disorder. Area under receiver-operator curve (AUC) and its nonparametric 95% CI were computed 96 .
RESULTS
Participant Characteristics
The mean age was 36 years, 73% were female, and 38% were married (Table 1) . Education levels completed were predominantly "Standard 4-8" (38%) and "Form 3-4" (34%), comparable to American elementary and high school, respectively. The majority of participants were unemployed but looking for work (69%). Median time living with HIV was 18 months; 44% reported being diagnosed with AIDS. Median CD4 count was 310 cells/μL (<50 cells/μL for 11 participants). Compared to males, females were significantly younger and less likely to be married, employed or diagnosed with AIDS, and had a lower CD4 count.
Prevalence of Depression Diagnoses and Severity
One-third of participants met PHQ-9 DSM-IV criteria for either MDD (13%) or ODD (21%). Fifty-three percent displayed mild or moderate depression severity (Table 1) . Floor effects for the PHQ-9 total score were negligible (only 10.4% scored zero). There was a significant interaction between CD4 count and gender on the PHQ-9 total score (p=0.048). Females had significantly higher depression, but only among participants with a CD4 count <200 (Table 1 , p=0.02). More importantly, after using ANCOVA to adjust for potentially confounding variables for which gender differed at least marginally (p<.10) in Table 1 (age; dichotomizations of marital status, education, employment and CD4 count; and AIDS diagnosis), the PHQ-9 score (dependent variable) was significantly (p=0.04) higher for females than males (adjusted means, 7.3 vs 5.6) in the entire sample regardless of the CD4 count, and the interaction was not significant.
Depression and HIV Progression
Regarding the interaction above, females with CD4 count <200 had a trend for a higher PHQ-9 total score than females with CD4 count ≥200 (p=0.14), and this trend was reversed for males (p=0.17). To investigate this counterintuitive result for males, a result consistent with our report on psychological distress 30 , we accounted for confounding covariates by using the ANCOVA model in the previous paragraph after removing the AIDS diagnosis (because it was correlated with the CD4 count); the interaction was not significant, and the adjusted mean PHQ-9 score was 7.0 and 6.7 for a CD4 count <200 and ≥200, respectively (p=0.78), revealing very little relationship between the CD4 count and depression, but a trend in the anticipated direction (e.g., 97 ) for the entire sample regardless of gender.
Construct Validity: Relationship Between PHQ-9 and General Health Rating PHQ-9 diagnostic categories differed significantly on general health rating (p=0.001). General health rating was best for no depressive disorder (adjusted mean, 63.3), lower for ODD (54.6) and worst for MDD (46.5) . MDD (p<.0001) and ODD (p=0.029) were each significantly different from no depressive disorder. However, MDD did not differ significantly from ODD.
PHQ-9 severity categories also differed significantly according to general health rating (p<.0001). Minimal depression severity differed significantly from all other depression severity categories with respect to general health rating. Those with severe depressive symptoms had significantly lower general health perceptions than those with mild depressive symptoms. General health rating steadily decreased as depression severity increased, a relationship that was not markedly different from that observed in two US validation samples (Fig. 1) . (For consistency, US samples excluded participants missing any PHQ-9 items.) Importantly, results did not vary significantly by age, gender or education (i.e., no significant interactions).
Construct Validity: Factor Analysis
The scree plot indicated one dominant dimension with a large decrease between first and second eigenvalues and small decreases thereafter (eigenvalues: 3.3, 1.0, 0.9, 0.8, 0.7, 0.7, 0.6, 0.5 and 0.5). Factor loadings ranged from 0.52 to 0.66 (i.e., above 0.40 cutoff) 98 . Factor loadings were strong (>0.50)
for four subgroup analyses: females (Table 2 , Part B), males ( Table 2 , Part C) and age groups dichotomized at median (age 18-35 and 36-61, not tabled). The percentage of total variance explained by the first factor was 37% (34%−40% for subgroups). Item-total correlations exceeded 0.37 (i.e., above the 0.30 cutoff) 98 in the total sample and four subgroups.
Low energy was the most highly endorsed item (mean, 1.10), as it was in US validation samples (Fig. 2) . All items except sleep problems were more highly endorsed in the western Kenya sample compared to US samples. The pattern of means across items was not substantially different from US samples (Fig. 2) .
Content Validity
Focus groups revealed that the PHQ-9 was generally well understood, acceptable and culturally relevant for all gender and age groups. Three findings emerged, applicable to all gender and age groups. First, interpreting opposite symptoms in Items 3, 5 and 8 was challenging for the majority of participants who repeatedly asked "Do you want both answers?" After discussion, participants understood the items referred to changes in behaviors in either direction. Second, participants understood the item scale and the 2-week recall period, but found it somewhat confusing to evaluate the item scale (e.g., "more than half the days") in relation to 2 weeks. Third, not surprisingly, participants reported interpreting and responding to PHQ-9 items mostly in the context of living with HIV. For example, Item 9 was perceived by both genders as the item referring most directly to living with HIV. Item 6 was perceived by males in the context of feeling guilty about getting infected and infecting his family with HIV. 
Operating Characteristics of the PHQ-2
The cutoff point of PHQ-2 ≥3 demonstrated high sensitivity (91.1%) and moderate specificity (76.8%) for PHQ-9 MDD (Table 3) . PHQ-2 ≥4 showed high specificity (93.4%) but low sensitivity (57.8%). Those with MDD were 3.93 times more likely to have a PHQ-2 score ≥3 than those without MDD. For any depressive disorder, PHQ-2 ≥3 was the best cutoff point for achieving high sensitivity (84.7%) and high specificity (95.2%); the positive predictive value was also high (90.1%) ( Table 3) . AUC was very high for MDD (0.91) and any depressive disorder (0.97) ( Table 3) .
DISCUSSION
Rates of depressive disorders were consistent with studies in sub-Saharan Africa. The PHQ-9 DSM-IV diagnostic and severity categories differed on general health rating, supporting construct validity. With a larger sample size, the difference between MDD and ODD may become significant, because their mean difference on general health rating was similar to the mean difference between ODD and no depressive disorder. The strong relationship between increasing PHQ-9 depression severity and worsening general health rating was consistent with two large US validation samples (see also 60 ), supporting construct validity. Factor analysis revealed acceptably high factor loadings on a major core depressive factor and adequate item discrimination values, supporting construct validity for not only the total sample, but also gender and age subgroups. Factor analysis of PHQ-9 with additional items revealed similarly acceptable loadings (0.43 to 0.63) among educated Nigerian army personnel 80 . Focus group interviews supported content validity, but suggested two potential modifications to the PHQ-9 instructions for western Kenyan culture (see Appendix). A common cultural practice in western Kenya is to respond "Nzuri" (fine) when asked how one is doing, even when one is not well. We especially wondered whether suicidal ideation would be selfreported. However, the mean for Item 9 was generally similar to US samples, relative to other item means (Fig. 2) . Furthermore, focus groups appeared willing and relieved to share feelings.
Coefficient alpha of 0.75 to 0.81 for gender/age subgroups implies a high degree of internal consistency. Values of 0.80 and 0.85 were reported among Nairobian low-literacy adult cancer patients 11 and Nigerian university students 46 , respec- Figure 1 . Relationship between PHQ-9 depression severity and general health rating. Vertical bars represent 95% confidence intervals of the adjusted means for the western Kenyan sample. The item-total correlation is corrected by excluding the item from the total score.
tively. Test-retest reliability of 0.59 for PHQ-9 total score is moderate. This ICC was better for older (0.65) and worse for younger (0.51) participants, and lower than previous PHQ-9 studies: 0.71 for a 14-day period among urban Kenyans with cancer 11 , 0.89 for a 30-day period among Nigerian university students 46 and 0.76 to 0.92 for a 7-day period among US and European outpatient samples 56, 57, 62, 73 . However, 0.59 may be acceptable given events between baseline and retest surveys that could have contributed to slight changes in depressive symptoms, including: (1) a national election with civil unrest and (2) some participants attended a support group session (data on who attended was not available). Consistent with previous research 58, [76] [77] [78] , the PHQ-2 demonstrated very good operating characteristics. The best cutoff point for sensitivity and specificity (≥3) provided very high specificity for any depressive disorder, an advantage in primary care and resource-constrained HIV clinics, where low specificity creates a problem by generating many false positives. This study has several limitations. First, we did not assess gold standard diagnoses using a structured interview. Second, results can only be generalized to western Kenyan adults living with HIV/AIDS and, strictly speaking, to those attending HIVrelated psychosocial support groups. Participant characteristics were similar to the AMPATH population from which participants were recruited. However, patients who attend support groups might have a better understanding of psychological symptoms and terminology. Third, language preference, variability in literacy and occasional assistance from research assistants may have impacted psychometrics and reproducibility of results. Moderate sample size prevented subgroup analyses for PHQ-2 operating characteristics and test-retest reliability of PHQ-9 diagnoses.
Future studies in western Kenya should assess PHQ-9 and PHQ-2 operating characteristics compared to structured diagnostic interviews and further psychometrics within demographic groups. The only study examining operating characteristics of PHQ-9 in sub-Saharan Africa found excellent results among Nigerian university students 46 . Studies should assess PHQ-9 responsiveness to treatment with anti- ODD = Other depressive disorder. AUC = Area under receiver-operator curve. TN = True negative = test negative (PHQ-2 < cutoff point), PHQ-9 disorder is absent. FN = False negative = test negative (PHQ-2 < cutoff point), PHQ-9 disorder present. FP = False positive = test positive (PHQ-2 ≥ cutoff point), PHQ-9 disorder absent. TP = True positive = test positive (PHQ-2 ≥ cutoff point), PHQ-9 disorder present. The likelihood ratio is undefined when specificity=100% and therefore was estimated for MMD at cutoff point 6 by assuming TN=301 and FP=1, and for any depressive disorder at cutoff points 5 and 6 by assuming TN=228 and FP=1. By definition, PHQ-2 ≥1 and ≥2 produce FN=0 and sensitivity=100% when compared to PHQ-9 DSM-IV algorithm for MDD or any depressive disorder. retroviral and psychosocial therapy, and whether PHQ-9 predicts adherence to antiretroviral therapy.
There are few mental health providers in Kenya 17 . Nevertheless, depression can be effectively treated in low-income countries 39, 100, 101 . The PHQ-9 appears to be a valid and reliable brief tool for assessing DSM-IV depressive disorders and depression severity in patients living with HIV/AIDS in resource-constrained western Kenya. Moreover, the PHQ-2 has good diagnostic operating characteristics as a two-item screener. The PHQ-9 and PHQ-2 may be useful to HIV-related medical providers in western Kenya who seek assessment tools for linking patients to psychosocial and psychiatric services in the continuum of care.
